Oswald Wagner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Oswald Wagner has a total of 210 co-authors. Here are the top co-authors by number of shared publications:
Georg Endler
Department of Medical and Chemical Laboratory Diagnostics, Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, AKH-Wien Waehringer Guertel 18-20, 1090, Vienna, Austria
10 shared publications- Christine Mannhalter
Medical University Vienna
7 shared publications - Helmuth Haslacher
Department of Laboratory Medicine , Medical University of Vienna , Vienna , Austria
6 shared publications Markus Exner
Department of Laboratory Medicine, Medical University, Vienna, Austria
5 shared publications- Thomas Perkmann
Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
5 shared publications Florian M. Kovar
Department of Trauma Surgery, Medical University of Vienna, Vienna, Austria
3 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (11) , 4292
Utilization Patterns of Hospital Biobank Samples: Time to First Use and Material-Specific Demand
Objectives: Biobanks collect biological material prospectively for future, yet unspecified research needs. The relationship between collection strategy and actual utilization remains poorly documented, yet understanding usage patterns is critical for resource allocation and planning. We aimed to analyze the time until first use and the utilization rates stratified by collection type and sample material. Methods: We conducted a retrospective analysis of metadata for all submissions (patient sample set per timepoint) deposited in 2019 (n = 13,666 from 56 collections) at the MedUni Wien Biobank. Collections were classified as prospective cohorts (without predefined hypotheses) or dedicated studies. Utilization was assessed at three levels: collections accessed, submissions from which at least one aliquot was requested, and total aliquots distributed. Results: Within 6–7 years, 31/56 collections (55%) were accessed, with 3466/13,666 submissions (25.4%) and 7565 of ~218,000 aliquots (3.5%) utilized. Among accessed collections, 21/35 were prospective cohorts, and 10/21 were dedicated studies. Median submission utilization was 54.2% (Q1–Q3: 25.2–93.1%). Among accessed submissions, conditional median time was 926 days (Q1–Q3: 438–1573). Serum was most frequently requested (24/31 projects). Aliquot requests per submission varied by material: median of 1 aliquot per sample for all materials except for citrate (2) and lithium heparin (5) plasma. Four material types showed no demand: buffy coat, ccfDNA, double-centrifuged citrate plasma, and saliva. Conclusions: The 3.5% aliquot-level utilization rate, numerically below internationally reported 10–20%, reflects metric granularity and the broad aliquoting strategy rather than low sample demand. Material-specific timing and demand patterns provide an evidence base for resource planning in hospital-based biobanks.
- 1 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (11) , 4292
Open AccessUtilization Patterns of Hospital Biobank Samples: Time to First Use and Material-Specific Demand
Objectives: Biobanks collect biological material prospectively for future, yet unspecified research needs. The relationship between collection strategy and actual utilization remains poorly documented, yet understanding usage patterns is critical for resource allocation and planning. We aimed to analyze the time until first use and the utilization rates stratified by collection type and sample material. Methods: We conducted a retrospective analysis of metadata for all submissions (patient sample set per timepoint) deposited in 2019 (n = 13,666 from 56 collections) at the MedUni Wien Biobank. Collections were classified as prospective cohorts (without predefined hypotheses) or dedicated studies. Utilization was assessed at three levels: collections accessed, submissions from which at least one aliquot was requested, and total aliquots distributed. Results: Within 6–7 years, 31/56 collections (55%) were accessed, with 3466/13,666 submissions (25.4%) and 7565 of ~218,000 aliquots (3.5%) utilized. Among accessed collections, 21/35 were prospective cohorts, and 10/21 were dedicated studies. Median submission utilization was 54.2% (Q1–Q3: 25.2–93.1%). Among accessed submissions, conditional median time was 926 days (Q1–Q3: 438–1573). Serum was most frequently requested (24/31 projects). Aliquot requests per submission varied by material: median of 1 aliquot per sample for all materials except for citrate (2) and lithium heparin (5) plasma. Four material types showed no demand: buffy coat, ccfDNA, double-centrifuged citrate plasma, and saliva. Conclusions: The 3.5% aliquot-level utilization rate, numerically below internationally reported 10–20%, reflects metric granularity and the broad aliquoting strategy rather than low sample demand. Material-specific timing and demand patterns provide an evidence base for resource planning in hospital-based biobanks.
- Open Access
Increasing test specificity without impairing sensitivity - lessons learned from SARS-CoV-2 serology
Background Serological tests are widely used in various medical disciplines for diagnostic and monitoring purposes. Unfortunately, the sensitivity and specificity of test systems is often poor, leaving room for false positive and false negative results. However, conventional methods used to increase specificity decrease sensitivity and vice versa. Using SARS-CoV-2 serology as an example, we propose here a novel testing strategy: the "Sensitivity Improved Two-Test" or "SIT 2 " algorithm. Methods SIT 2 involves confirmatory re-testing of samples with results falling in a predefined retesting-zone of an initial screening test, with adjusted cut-offs to increase sensitivity. We verified and compared the performance of SIT 2 to single tests and orthogonal testing (OTA) in an Austrian cohort (1,117 negative, 64 post-COVID positive samples) and validated the algorithm in an independent British cohort (976 negatives, 536 positives). Results The specificity of SIT 2 was superior to single tests and non-inferior to OTA. The sensitivity was maintained or even improved using SIT 2 when compared to single tests or OTA. SIT 2 allowed correct identification of infected individuals even when a live virus neutralization assay could not detect antibodies. Compared to single testing or OTA, SIT 2 significantly reduced total test errors to 0.46% (0.24-0.65) or 1.60% (0.94-2.38) at both 5% or 20% seroprevalence. Conclusion For SARS-CoV-2 serology, SIT 2 proved to be the best diagnostic choice at both 5% and 20% seroprevalence in all tested scenarios. It is an easy to apply algorithm and can potentially be helpful for the serology of other infectious diseases.
Open AccessIncreasing test specificity without impairing sensitivity - lessons learned from SARS-CoV-2 serology
Background Serological tests are widely used in various medical disciplines for diagnostic and monitoring purposes. Unfortunately, the sensitivity and specificity of test systems is often poor, leaving room for false positive and false negative results. However, conventional methods used to increase specificity decrease sensitivity and vice versa. Using SARS-CoV-2 serology as an example, we propose here a novel testing strategy: the "Sensitivity Improved Two-Test" or "SIT 2 " algorithm. Methods SIT 2 involves confirmatory re-testing of samples with results falling in a predefined retesting-zone of an initial screening test, with adjusted cut-offs to increase sensitivity. We verified and compared the performance of SIT 2 to single tests and orthogonal testing (OTA) in an Austrian cohort (1,117 negative, 64 post-COVID positive samples) and validated the algorithm in an independent British cohort (976 negatives, 536 positives). Results The specificity of SIT 2 was superior to single tests and non-inferior to OTA. The sensitivity was maintained or even improved using SIT 2 when compared to single tests or OTA. SIT 2 allowed correct identification of infected individuals even when a live virus neutralization assay could not detect antibodies. Compared to single testing or OTA, SIT 2 significantly reduced total test errors to 0.46% (0.24-0.65) or 1.60% (0.94-2.38) at both 5% or 20% seroprevalence. Conclusion For SARS-CoV-2 serology, SIT 2 proved to be the best diagnostic choice at both 5% and 20% seroprevalence in all tested scenarios. It is an easy to apply algorithm and can potentially be helpful for the serology of other infectious diseases.
- 15 September 2015
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 127 (23-24) , 924-930
Subclinical hypothyroidism and mortality in a large Austrian cohort: a possible impact on treatment?
Summary Background Clinical implications of subclinical hypothyroidism (SCH) are still matter of intense debate, resulting in the controversial discussion whether subclinical hypothyroidism should be treated. We performed a cohort study to evaluate the impact of subclinical hypothyroidism on vascular and overall mortality. Methods Between 02/1993 and 03/2004, a total of 103,135 persons attending the General Hospital Vienna with baseline serum thyrotropin (TSH, thyroid-stimulating hormone) and free thyroxin (fT4) measurements could be enrolled in a retrospective cohort study. Subclinical hypothyroidism was defined by elevated TSH ranging from 4.5 to 20.0 mIU/L and normal fT4 concentration (0.7–1.7 ng/dL). Overall and vascular mortality as primary endpoints were assessed via record linkage with the Austrian Death Registry. Results A total of 80,490 subjects fulfilled inclusion criteria of whom 3934 participants (3.7 %) were classified as SCH (868 males and 3066 females, median age 48 years). The mean follow-up among the 80,490 subjects was 4.1 years yielding an observation period of 373,301 person-years at risk. In a multivariate Cox regression model adjusted for age and gender TSH levels showed a dose-dependent association with all-cause mortality. The association between SCH and overall or vascular mortality was stronger in men below 60 years compared to older males or females. Conclusion Our data support the hypothesis that SCH might represent an independent risk factor for overall and vascular mortality, especially in men below 60 years. Whether this group would benefit from replacement therapy should be evaluated in interventional studies.
- 15 September 2015
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 127 (23-24) , 924-930
Subclinical hypothyroidism and mortality in a large Austrian cohort: a possible impact on treatment?
Summary Background Clinical implications of subclinical hypothyroidism (SCH) are still matter of intense debate, resulting in the controversial discussion whether subclinical hypothyroidism should be treated. We performed a cohort study to evaluate the impact of subclinical hypothyroidism on vascular and overall mortality. Methods Between 02/1993 and 03/2004, a total of 103,135 persons attending the General Hospital Vienna with baseline serum thyrotropin (TSH, thyroid-stimulating hormone) and free thyroxin (fT4) measurements could be enrolled in a retrospective cohort study. Subclinical hypothyroidism was defined by elevated TSH ranging from 4.5 to 20.0 mIU/L and normal fT4 concentration (0.7–1.7 ng/dL). Overall and vascular mortality as primary endpoints were assessed via record linkage with the Austrian Death Registry. Results A total of 80,490 subjects fulfilled inclusion criteria of whom 3934 participants (3.7 %) were classified as SCH (868 males and 3066 females, median age 48 years). The mean follow-up among the 80,490 subjects was 4.1 years yielding an observation period of 373,301 person-years at risk. In a multivariate Cox regression model adjusted for age and gender TSH levels showed a dose-dependent association with all-cause mortality. The association between SCH and overall or vascular mortality was stronger in men below 60 years compared to older males or females. Conclusion Our data support the hypothesis that SCH might represent an independent risk factor for overall and vascular mortality, especially in men below 60 years. Whether this group would benefit from replacement therapy should be evaluated in interventional studies.
- 17 April 2012
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 124 (7-8) , 245-250
CK/CK-MB ratio as an indirect predictor for survival in polytraumatized patients
Hintergrund Das richtige Erkennen des Schweregrades einer Verletzung ist entscheidend für die Triage und die Behandlung von Schwerstverletzten. Das frühe Abschätzen des Mortalitätsrisikos bei lebensgefährlich verletzten Patienten ist eine Grundvoraussetzung für eine adäquate und zielführende Behandlung. Aktuelle Risikoeinschätzung basiert auf klinischen Diagnosen und Scoringsystemen. In unsere Studie haben wir die Hypothese untersucht, dass ein einfacher Labortest, CK/CK-MB Ratio, möglicherweise die Risikoeinschätzung für die Behandlung von Schwerstverletzten verbessern könnte. Methodik In einem Zeitraum von 9 Jahren (2002–2011) konnten 328 nicht selektierte Polytraumapatienten an einem Level I Krankenhaus in unsere Studie inkludiert werden. Die Daten wurden aus dem elektronischen Patienteninformationssystem erhoben, welches im September 1992 erstellt wurde. Ergebnisse In unserer Studienpopulation konnten wir eine negative Korrelation zwischen ISS (Injury Severity Score) und Leukozyten. Eine positive Korrelation konnte für Leberenzyme und CK-MB erhoben werden. Die Korrelation zwischen ISS und Na^+ ^ war signifikant. Zwischen ISS, K^+ und Hb/HK konnte keine Korrelation beobachtet werden. Exitus war assoziiert mit ISS, erhöhten Thrombozyten, CK, CK-MB, CRP, Crea and Na^+. Schlussfolgerung Mit unserer Studie konnten wir eine signifikante Korrelation zwischen CK-MB Werten und dem Gesamtüberleben in Polytrauma-Patienten zeigen. Daher wäre es möglich, dass in Zukunft CK-MB Werte als Vorhersageparameter für das Überleben dienen könnten. Unsere Ergebnisse müssen durch weiter prospektive Studien bestätigt werden. Background Accurate assessment of injury severity is critical for decision making related to the prevention, triage, and treatment of several injured patients. Early estimation of mortality risk of critically injured patients is mandatory for adequate therapeutic strategies. Current risk stratification relies on clinical diagnosis and scoring systems. In our study, we hypothesized whether a simple laboratory test, the CK/CK-MB ratio, could help improving risk prediction in severely traumatized patients. Methods In a 9-year period, 328 nonselected trauma patients were included in our retrospective study at a Level I Trauma Center up to September 2002. Data for this study were obtained from our computerized trauma database, established in September 1992. Results In our study population, we could show a negative correlation between Injury Severity Score (ISS) and leukocytes. A positive correlation was detected for liver enzymes and CK-MB. The correlation between ISS and Na^+ was significant. No correlation between ISS, K^+,^ and Hb/Ht could be observed. Exitus was associated with ISS, alteration in thrombocytes, CK, CK-MB, CRP, Crea, and Na^+. Conclusion In our study population, CK-MB levels showed a significant correlation with overall surveillance in polytraumatized patients. In our opinion, this might suggest that CK-MB levels could be taken as an indirect predictor for survival. Our findings need to be proven in further prospective clinical trials.
- 17 April 2012
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 124 (7-8) , 245-250
CK/CK-MB ratio as an indirect predictor for survival in polytraumatized patients
Hintergrund Das richtige Erkennen des Schweregrades einer Verletzung ist entscheidend für die Triage und die Behandlung von Schwerstverletzten. Das frühe Abschätzen des Mortalitätsrisikos bei lebensgefährlich verletzten Patienten ist eine Grundvoraussetzung für eine adäquate und zielführende Behandlung. Aktuelle Risikoeinschätzung basiert auf klinischen Diagnosen und Scoringsystemen. In unsere Studie haben wir die Hypothese untersucht, dass ein einfacher Labortest, CK/CK-MB Ratio, möglicherweise die Risikoeinschätzung für die Behandlung von Schwerstverletzten verbessern könnte. Methodik In einem Zeitraum von 9 Jahren (2002–2011) konnten 328 nicht selektierte Polytraumapatienten an einem Level I Krankenhaus in unsere Studie inkludiert werden. Die Daten wurden aus dem elektronischen Patienteninformationssystem erhoben, welches im September 1992 erstellt wurde. Ergebnisse In unserer Studienpopulation konnten wir eine negative Korrelation zwischen ISS (Injury Severity Score) und Leukozyten. Eine positive Korrelation konnte für Leberenzyme und CK-MB erhoben werden. Die Korrelation zwischen ISS und Na^+ ^ war signifikant. Zwischen ISS, K^+ und Hb/HK konnte keine Korrelation beobachtet werden. Exitus war assoziiert mit ISS, erhöhten Thrombozyten, CK, CK-MB, CRP, Crea and Na^+. Schlussfolgerung Mit unserer Studie konnten wir eine signifikante Korrelation zwischen CK-MB Werten und dem Gesamtüberleben in Polytrauma-Patienten zeigen. Daher wäre es möglich, dass in Zukunft CK-MB Werte als Vorhersageparameter für das Überleben dienen könnten. Unsere Ergebnisse müssen durch weiter prospektive Studien bestätigt werden. Background Accurate assessment of injury severity is critical for decision making related to the prevention, triage, and treatment of several injured patients. Early estimation of mortality risk of critically injured patients is mandatory for adequate therapeutic strategies. Current risk stratification relies on clinical diagnosis and scoring systems. In our study, we hypothesized whether a simple laboratory test, the CK/CK-MB ratio, could help improving risk prediction in severely traumatized patients. Methods In a 9-year period, 328 nonselected trauma patients were included in our retrospective study at a Level I Trauma Center up to September 2002. Data for this study were obtained from our computerized trauma database, established in September 1992. Results In our study population, we could show a negative correlation between Injury Severity Score (ISS) and leukocytes. A positive correlation was detected for liver enzymes and CK-MB. The correlation between ISS and Na^+ was significant. No correlation between ISS, K^+,^ and Hb/Ht could be observed. Exitus was associated with ISS, alteration in thrombocytes, CK, CK-MB, CRP, Crea, and Na^+. Conclusion In our study population, CK-MB levels showed a significant correlation with overall surveillance in polytraumatized patients. In our opinion, this might suggest that CK-MB levels could be taken as an indirect predictor for survival. Our findings need to be proven in further prospective clinical trials.
- 4 November 2010
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 41 (4) , 365-371
Polymorphism of the palladin gene and cardiovascular outcome in patients with atherosclerosis
- 4 November 2010
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 41 (4) , 365-371
Polymorphism of the palladin gene and cardiovascular outcome in patients with atherosclerosis
- Open Access
- 28 July 2010
- Published by Springer Nature in Molecular Cancer
- Vol. 9 (1) , 200
Transcriptome analysis of human cancer reveals a functional role of Heme Oxygenase-1 in tumor cell adhesion
Background: Heme Oxygenase-1 (HO-1) is expressed in many cancers and promotes growth and survival of neoplastic cells. Recently, HO-1 has been implicated in tumor cell invasion and metastasis. However, the molecular mechanisms underlying these biologic effects of HO-1 remain largely unknown. To identify a common mechanism of action of HO-1 in cancer, we determined the global effect of HO-1 on the transcriptome of multiple tumor entities and identified a universal HO-1-associated gene expression signature. Results: Genome-wide expression profiling of Heme Oxygenase-1 expressing versus HO-1 silenced BeWo choriocarcinoma cells as well as a comparative meta-profiling of the preexisting expression database of 190 human tumors of 14 independent cancer types led to the identification of 14 genes, the expression of which correlated strongly and universally with that of HO-1 (P = 0.00002). These genes included regulators of cell plasticity and extracellular matrix (ECM) remodeling (MMP2, ADAM8, TGFB1, BGN, COL21A1, PXDN), signaling (CRIP2, MICB), amino acid transport and glycosylation (SLC7A1 and ST3GAL2), estrogen and phospholipid biosynthesis (AGPAT2 and HSD17B1), protein stabilization (IFI30), and phosphorylation (ALPPL2). We selected PXDN, an adhesion molecule involved in ECM formation, for further analysis and functional characterization. Immunofluorescence and Western blotting confirmed the positive correlation of expression of PXDN and HO-1 in BeWo cancer cells as well as co-localization of these two proteins in invasive extravillous trophoblast cells. Modulation of HO-1 expression in both loss-of and gain-of function cell models (BeWo and 607B melanoma cells, respectively) demonstrated a direct relationship of HO-1 expression with cell adhesion to Fibronectin and Laminin coated wells. The adhesion-promoting effects of HO-1 were dependent on PXDN expression, as loss of PXDN in HO-1 expressing BeWo and 607B cells led to reduced cell attachment to Laminin and Fibronectin coated wells. Conclusions: Collectively, our results show that HO-1 expression determines a distinct 'molecular signature' in cancer cells, which is enriched in genes associated with tumorigenesis. The protein network downstream of HO-1 modulates adhesion, signaling, transport, and other critical cellular functions of neoplastic cells and thus promotes tumor cell growth and dissemination.
- 28 July 2010
- Published by Springer Nature in Molecular Cancer
- Vol. 9 (1) , 200
Open AccessTranscriptome analysis of human cancer reveals a functional role of Heme Oxygenase-1 in tumor cell adhesion
Background: Heme Oxygenase-1 (HO-1) is expressed in many cancers and promotes growth and survival of neoplastic cells. Recently, HO-1 has been implicated in tumor cell invasion and metastasis. However, the molecular mechanisms underlying these biologic effects of HO-1 remain largely unknown. To identify a common mechanism of action of HO-1 in cancer, we determined the global effect of HO-1 on the transcriptome of multiple tumor entities and identified a universal HO-1-associated gene expression signature. Results: Genome-wide expression profiling of Heme Oxygenase-1 expressing versus HO-1 silenced BeWo choriocarcinoma cells as well as a comparative meta-profiling of the preexisting expression database of 190 human tumors of 14 independent cancer types led to the identification of 14 genes, the expression of which correlated strongly and universally with that of HO-1 (P = 0.00002). These genes included regulators of cell plasticity and extracellular matrix (ECM) remodeling (MMP2, ADAM8, TGFB1, BGN, COL21A1, PXDN), signaling (CRIP2, MICB), amino acid transport and glycosylation (SLC7A1 and ST3GAL2), estrogen and phospholipid biosynthesis (AGPAT2 and HSD17B1), protein stabilization (IFI30), and phosphorylation (ALPPL2). We selected PXDN, an adhesion molecule involved in ECM formation, for further analysis and functional characterization. Immunofluorescence and Western blotting confirmed the positive correlation of expression of PXDN and HO-1 in BeWo cancer cells as well as co-localization of these two proteins in invasive extravillous trophoblast cells. Modulation of HO-1 expression in both loss-of and gain-of function cell models (BeWo and 607B melanoma cells, respectively) demonstrated a direct relationship of HO-1 expression with cell adhesion to Fibronectin and Laminin coated wells. The adhesion-promoting effects of HO-1 were dependent on PXDN expression, as loss of PXDN in HO-1 expressing BeWo and 607B cells led to reduced cell attachment to Laminin and Fibronectin coated wells. Conclusions: Collectively, our results show that HO-1 expression determines a distinct 'molecular signature' in cancer cells, which is enriched in genes associated with tumorigenesis. The protein network downstream of HO-1 modulates adhesion, signaling, transport, and other critical cellular functions of neoplastic cells and thus promotes tumor cell growth and dissemination.
- 25 June 2010
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 122 (11-12) , 334-340
Coagulation factor VIII levels are associated with long-term survival – interactions with gender in a large hospital-based cohort
HINTERGRUND: In der Literatur ist eine gesteigerte Faktor VIII Aktivität mit einem erhöhten Risiko für arterielle und venöse Thrombosen assoziiert. Die vorliegende Studie untersucht den Einfluss von Faktor VIII Spiegeln auf die Gesamtmortalität unter Berücksichtigung geschlechtsspezifischer Unterschiede in einer groß angelegten Studie in Österreich. PATIENTEN UND METHODE: In dieser Studie wurden zwischen 1991 und 2003, 11203 Patienten eingeschlossen. Der durchschnittliche Beobachtungszeitraum betrug 5 Jahre mit insgesamt 46000 Personenjahren. Insgesamt sind während des Beobachtungszeitraumes 17,1 % der Studienpopulation verstorben. ERGEBNISSE: Im Vergleich zu Patienten in der Referenzkategorie (FVIII: C 313 % Kategorie (höchste Dezile, alle p < 0,05). Die Assoziation zwischen FVIII: C Spiegeln und Mortalität bleibt unverändert hinsichtlich nicht Krebs-assoziierte Mortalität, vaskuläre Mortalität und ischämischer Herzerkrankungen. Im Vergleich zu Männern, haben Frauen mit erhöhten FVIII: C Spiegeln ein schlechteres Outcome, resultierend in höheren Hazard Ratios 6,8 (95 % CI: 4,6 – 9,9) im Vergleich zu Männern (HR: 3,4 (95 % CI: 2,6 – 4,5)). SCHLUSSFOLGERUNGEN: In unserer groß angelegten Studie konnten wir erstmals zeigen, dass FVIII: C Plasma Aktivität mit einer erhöhten Gesamtmortalität assoziiert ist. Außerdem scheint es auch eine geschlechtsspezifische Interaktion von FVIII: C zu geben. Vor allem bei Frauen mit erhöhten FVIII: C Spiegeln dürfte es daher hilfreich sein Hochrisikogruppen zu identifizieren, die von individuellen Präventionsstrategien profitieren würden. INTRODUCTION: Elevated coagulation factor VIII activity has been associated with increased risk for both venous and arterial thrombosis. The current study evaluated the influence of Factor VIII levels and interactions with gender on all cause mortality in a large Austrian cohort. PATIENTS AND METHODS: During 1991 and 2003, 11203 individuals, first ever request for laboratory analyses of FVIII: C, age ≥18 years, were included in this study. The median observation period was 5 years covering a total of 46000 person-years. The death rate was 17.1%. RESULTS: Compared to individuals within the reference category (FVIII: C 313% category (highest decile, all p < 0.05). The association between FVIII: C levels and mortality remained essentially unchanged when considering non-cancer mortality, all cause vascular mortality or mortality due to ischemic heart disease. Compared to males females with elevated FVIII: C had a worse outcome resulting in higher hazard ratios reaching 6.8 (95% CI: 4.6–9.9) within the highest decile compared to males (HR: 3.4 (95% CI: 2.6–4.5)). CONCLUSIONS: In our large patient cohort we might be able to demonstrate for the first time that FVIII: C plasma activity is strongly associated with all cause mortality. Additionally, FVIII: C appears to interact with gender. Especially in women FVIII: C might help identifying high-risk cohorts, which might benefit from individualized prevention strategies.
- 25 June 2010
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 122 (11-12) , 334-340
Coagulation factor VIII levels are associated with long-term survival – interactions with gender in a large hospital-based cohort
HINTERGRUND: In der Literatur ist eine gesteigerte Faktor VIII Aktivität mit einem erhöhten Risiko für arterielle und venöse Thrombosen assoziiert. Die vorliegende Studie untersucht den Einfluss von Faktor VIII Spiegeln auf die Gesamtmortalität unter Berücksichtigung geschlechtsspezifischer Unterschiede in einer groß angelegten Studie in Österreich. PATIENTEN UND METHODE: In dieser Studie wurden zwischen 1991 und 2003, 11203 Patienten eingeschlossen. Der durchschnittliche Beobachtungszeitraum betrug 5 Jahre mit insgesamt 46000 Personenjahren. Insgesamt sind während des Beobachtungszeitraumes 17,1 % der Studienpopulation verstorben. ERGEBNISSE: Im Vergleich zu Patienten in der Referenzkategorie (FVIII: C 313 % Kategorie (höchste Dezile, alle p < 0,05). Die Assoziation zwischen FVIII: C Spiegeln und Mortalität bleibt unverändert hinsichtlich nicht Krebs-assoziierte Mortalität, vaskuläre Mortalität und ischämischer Herzerkrankungen. Im Vergleich zu Männern, haben Frauen mit erhöhten FVIII: C Spiegeln ein schlechteres Outcome, resultierend in höheren Hazard Ratios 6,8 (95 % CI: 4,6 – 9,9) im Vergleich zu Männern (HR: 3,4 (95 % CI: 2,6 – 4,5)). SCHLUSSFOLGERUNGEN: In unserer groß angelegten Studie konnten wir erstmals zeigen, dass FVIII: C Plasma Aktivität mit einer erhöhten Gesamtmortalität assoziiert ist. Außerdem scheint es auch eine geschlechtsspezifische Interaktion von FVIII: C zu geben. Vor allem bei Frauen mit erhöhten FVIII: C Spiegeln dürfte es daher hilfreich sein Hochrisikogruppen zu identifizieren, die von individuellen Präventionsstrategien profitieren würden. INTRODUCTION: Elevated coagulation factor VIII activity has been associated with increased risk for both venous and arterial thrombosis. The current study evaluated the influence of Factor VIII levels and interactions with gender on all cause mortality in a large Austrian cohort. PATIENTS AND METHODS: During 1991 and 2003, 11203 individuals, first ever request for laboratory analyses of FVIII: C, age ≥18 years, were included in this study. The median observation period was 5 years covering a total of 46000 person-years. The death rate was 17.1%. RESULTS: Compared to individuals within the reference category (FVIII: C 313% category (highest decile, all p < 0.05). The association between FVIII: C levels and mortality remained essentially unchanged when considering non-cancer mortality, all cause vascular mortality or mortality due to ischemic heart disease. Compared to males females with elevated FVIII: C had a worse outcome resulting in higher hazard ratios reaching 6.8 (95% CI: 4.6–9.9) within the highest decile compared to males (HR: 3.4 (95% CI: 2.6–4.5)). CONCLUSIONS: In our large patient cohort we might be able to demonstrate for the first time that FVIII: C plasma activity is strongly associated with all cause mortality. Additionally, FVIII: C appears to interact with gender. Especially in women FVIII: C might help identifying high-risk cohorts, which might benefit from individualized prevention strategies.
- 1 October 2009
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 121 (19-20) , 638-643
The EGF 61A/G polymorphism – a predictive marker for recurrence of liver metastases from colorectal cancer
HINTERGRUND: Der epidermale Wachstumsfaktor (EGF) spielt eine bedeutende Rolle in der Tumorentstehung. Variationen in der DNA Sequenz des EGF Gens, können zu einer Erhöhung der EGF Aktivität führen, von der man annimmt, dass sie das Tumorwachstum beeinflusst. Die aktuelle Studie untersucht den Einfluss des EGF 61A/G Polymorphismus auf das Wiederauftreten von Lebermetastasen beim kolorektalen Karzinom nach Operation. METHODE: Der EGF 61A/G Polymorphismus wurde retrospektiv in 268 fortlaufenden Patienten beiderlei Geschlechts bestimmt: 175 (65%) männliche und 93 (35%) weibliche Patienten, welche chirurgisch kurativ mit (R0) bei Lebermetastasen im Rahmen eines kolorektalen Karzinoms behandelt wurden. ERGEBNISSE: Von den 268 Patienten, hatten 81 (30%) die häufigste (Wildtyp) Variante EGF 61 A/A, 137 (51%) waren heterozygot EGF 61 A/G und 50 (19%) waren homozygot EGF 61 G/G. Adjustiert nach Alter, Geschlecht, UICC Staging und Tumorlokalisation konnten wir ein 1.6 fach höheres Risiko für das Wiederauftreten von Lebermetastasen (HR: 1,6; 95% CI: 1,0–2,5 p = 0,06) bei EGF 61 G/G Homozygoten verglichen mit Trägern des EGF 61 A Allels feststellen. Dieser Effekt war in jungen Patienten (≤ 65 Jahren), welche ein 2.0-fach höheres Risiko für das neuerliche Auftreten von Lebermetastasen hatten (HR: 2,0; 95% CI: 1,1–3,5 p = 0,021), stärker. Bei Patienten über 65 Jahren konnte kein Effekt nachgewiesen werden. Interessanter Weise konnten wir feststellen, dass männliche Patienten mit EGF G/G ein 1,6 fach höheres Risiko für das Wiederauftreten von Metastasen hatten (HR: 1,6; 95% CI: 1,0–2,5 p = 0,07). Eine signifikante Korrelation (p = 0,033) zwischen der Dukes Klassifikation und homozygot EGF 61 G/G konnte ebenfalls festgestellt werden. KONKLUSION: Mit unseren Ergebnissen konnten wir zeigen, auch unter Berücksichtigung unserer kleinen Patientenpopulation, dass Träger des EGF 61G/G Genotyps ein höheres Risiko für neuerliche Lebermetastasen haben – eine Vermutung, die allerdings durch weitere Studien bestätigt werden muss. BACKGROUND: Epidermal growth factor (EGF) plays an important role in tumorigenesis. Variations in the DNA sequence of the gene EGF can lead to alterations in EGF activity, which is suspected to influence tumor progression. This retrospective study aimed to investigate the influence of EGF 61A/G polymorphism on the recurrence of liver metastases after hepatic surgery in patients with colorectal cancer. METHODS: EGF 61A/G polymorphism was determined in 268 consecutive patients (175 [65%] men and 93 [35%] women, mean age 62 ± 10.3 years) who had liver metastases at primary diagnosis and were treated by surgery with curative intent (R0) for liver metastases from colorectal cancer. RESULTS: Overall, 81 of 268 (30%) patients exhibited wild-type EGF 61 A/A, 137 (51%) were heterozygous EGF 61 A/G and 50 (19%) were homozygous EGF 61 G/G. After adjusting for age, sex, UICC stage and tumor location, we observed a trend-wise 1.6-fold increased risk for hepatic recurrence (HR 1.6; 95% CI 1.0–2.5, P = 0.06) in individuals with the G/G genotype compared with carriers of the A-allele. The effect was much more pronounced in younger patients (≤ 65 years), who showed a 2.0-fold increased risk of hepatic recurrence (HR 2.0; 95% CI 1.1–3.5, P = 0.021). No effect was observed in older patients (≥ 65 years). Interestingly, male patients with EGF G/G had a 1.6-fold higher risk of recurrence (HR 1.6; 95% CI 1.0–2.5, P = 0.07). A significant correlation (P = 0.033) was detected between Dukes classification and the homozygous 61 G/G genotype. CONCLUSION: Despite the limitations of our study, the retrospective results indicate that carriers of the EGF polymorphism might be at higher risk of developing liver recurrences. If confirmed in subsequent studies, genotyping for the EGF A/G variant might help in identification of patients at high risk of recurrence of liver metastases.
- 1 October 2009
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 121 (19-20) , 638-643
The EGF 61A/G polymorphism – a predictive marker for recurrence of liver metastases from colorectal cancer
HINTERGRUND: Der epidermale Wachstumsfaktor (EGF) spielt eine bedeutende Rolle in der Tumorentstehung. Variationen in der DNA Sequenz des EGF Gens, können zu einer Erhöhung der EGF Aktivität führen, von der man annimmt, dass sie das Tumorwachstum beeinflusst. Die aktuelle Studie untersucht den Einfluss des EGF 61A/G Polymorphismus auf das Wiederauftreten von Lebermetastasen beim kolorektalen Karzinom nach Operation. METHODE: Der EGF 61A/G Polymorphismus wurde retrospektiv in 268 fortlaufenden Patienten beiderlei Geschlechts bestimmt: 175 (65%) männliche und 93 (35%) weibliche Patienten, welche chirurgisch kurativ mit (R0) bei Lebermetastasen im Rahmen eines kolorektalen Karzinoms behandelt wurden. ERGEBNISSE: Von den 268 Patienten, hatten 81 (30%) die häufigste (Wildtyp) Variante EGF 61 A/A, 137 (51%) waren heterozygot EGF 61 A/G und 50 (19%) waren homozygot EGF 61 G/G. Adjustiert nach Alter, Geschlecht, UICC Staging und Tumorlokalisation konnten wir ein 1.6 fach höheres Risiko für das Wiederauftreten von Lebermetastasen (HR: 1,6; 95% CI: 1,0–2,5 p = 0,06) bei EGF 61 G/G Homozygoten verglichen mit Trägern des EGF 61 A Allels feststellen. Dieser Effekt war in jungen Patienten (≤ 65 Jahren), welche ein 2.0-fach höheres Risiko für das neuerliche Auftreten von Lebermetastasen hatten (HR: 2,0; 95% CI: 1,1–3,5 p = 0,021), stärker. Bei Patienten über 65 Jahren konnte kein Effekt nachgewiesen werden. Interessanter Weise konnten wir feststellen, dass männliche Patienten mit EGF G/G ein 1,6 fach höheres Risiko für das Wiederauftreten von Metastasen hatten (HR: 1,6; 95% CI: 1,0–2,5 p = 0,07). Eine signifikante Korrelation (p = 0,033) zwischen der Dukes Klassifikation und homozygot EGF 61 G/G konnte ebenfalls festgestellt werden. KONKLUSION: Mit unseren Ergebnissen konnten wir zeigen, auch unter Berücksichtigung unserer kleinen Patientenpopulation, dass Träger des EGF 61G/G Genotyps ein höheres Risiko für neuerliche Lebermetastasen haben – eine Vermutung, die allerdings durch weitere Studien bestätigt werden muss. BACKGROUND: Epidermal growth factor (EGF) plays an important role in tumorigenesis. Variations in the DNA sequence of the gene EGF can lead to alterations in EGF activity, which is suspected to influence tumor progression. This retrospective study aimed to investigate the influence of EGF 61A/G polymorphism on the recurrence of liver metastases after hepatic surgery in patients with colorectal cancer. METHODS: EGF 61A/G polymorphism was determined in 268 consecutive patients (175 [65%] men and 93 [35%] women, mean age 62 ± 10.3 years) who had liver metastases at primary diagnosis and were treated by surgery with curative intent (R0) for liver metastases from colorectal cancer. RESULTS: Overall, 81 of 268 (30%) patients exhibited wild-type EGF 61 A/A, 137 (51%) were heterozygous EGF 61 A/G and 50 (19%) were homozygous EGF 61 G/G. After adjusting for age, sex, UICC stage and tumor location, we observed a trend-wise 1.6-fold increased risk for hepatic recurrence (HR 1.6; 95% CI 1.0–2.5, P = 0.06) in individuals with the G/G genotype compared with carriers of the A-allele. The effect was much more pronounced in younger patients (≤ 65 years), who showed a 2.0-fold increased risk of hepatic recurrence (HR 2.0; 95% CI 1.1–3.5, P = 0.021). No effect was observed in older patients (≥ 65 years). Interestingly, male patients with EGF G/G had a 1.6-fold higher risk of recurrence (HR 1.6; 95% CI 1.0–2.5, P = 0.07). A significant correlation (P = 0.033) was detected between Dukes classification and the homozygous 61 G/G genotype. CONCLUSION: Despite the limitations of our study, the retrospective results indicate that carriers of the EGF polymorphism might be at higher risk of developing liver recurrences. If confirmed in subsequent studies, genotyping for the EGF A/G variant might help in identification of patients at high risk of recurrence of liver metastases.
- 15 September 2009
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 39 (10) , 860-865
Sex differences in the association between albumin and all‐cause and vascular mortality
Background Low serum albumin levels are associated with cardiovascular disease and mortality risk. This study evaluated the predictive value of low serum albumin for all‐cause‐mortality in a large Viennese patient cohort and investigated sex differences in the association between serum albumin and mortality.Materials and methods Serum albumin concentrations of 285 930 patients, who attended the General Hospital Vienna between 1992 and 2002, were evaluated and linked with the Austrian Death Registry. The median observation period was 7·4 ± 4·0 years and the death rate was 16·8%. For Cox regression analysis, albumin levels were divided into deciles, the highest category served as reference value. To analyse associations between albumin and mortality independent of liver function, results were adjusted for cholinesterase, which indicates protein synthesis capacity of the liver.Results Hazard ratios for all‐cause‐mortality increased linearly with decreasing albumin levels from 1·05 in the 9th to 2·98 in the 1st decile. Adjusted for cholinesterase, the relative risk for mortality was still 1·91 in the lowest category. Compared with women, men had an average 50% increased risk of death in almost every decile, adjusting for cholinesterase reduced the sex difference to a 10–20% higher mortality risk for men. In critically ill patients, hazard ratios for all‐cause‐mortality ranged from 4·5 in the 9th decile to 9·5 in the lowest albumin category.Conclusion This study demonstrates a strong inverse association between serum albumin and mortality in a large patient cohort. The predictive value of low albumin was remarkably higher in men than in women.
- 15 September 2009
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 39 (10) , 860-865
Sex differences in the association between albumin and all‐cause and vascular mortality
Background Low serum albumin levels are associated with cardiovascular disease and mortality risk. This study evaluated the predictive value of low serum albumin for all‐cause‐mortality in a large Viennese patient cohort and investigated sex differences in the association between serum albumin and mortality.Materials and methods Serum albumin concentrations of 285 930 patients, who attended the General Hospital Vienna between 1992 and 2002, were evaluated and linked with the Austrian Death Registry. The median observation period was 7·4 ± 4·0 years and the death rate was 16·8%. For Cox regression analysis, albumin levels were divided into deciles, the highest category served as reference value. To analyse associations between albumin and mortality independent of liver function, results were adjusted for cholinesterase, which indicates protein synthesis capacity of the liver.Results Hazard ratios for all‐cause‐mortality increased linearly with decreasing albumin levels from 1·05 in the 9th to 2·98 in the 1st decile. Adjusted for cholinesterase, the relative risk for mortality was still 1·91 in the lowest category. Compared with women, men had an average 50% increased risk of death in almost every decile, adjusting for cholinesterase reduced the sex difference to a 10–20% higher mortality risk for men. In critically ill patients, hazard ratios for all‐cause‐mortality ranged from 4·5 in the 9th decile to 9·5 in the lowest albumin category.Conclusion This study demonstrates a strong inverse association between serum albumin and mortality in a large patient cohort. The predictive value of low albumin was remarkably higher in men than in women.
- Open Access
- 1 February 2008
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 54 (2) , 343-349
C-Reactive Protein and All-Cause Mortality in a Large Hospital-Based Cohort
Background: C-reactive protein (CRP), an acute-phase protein, is a sensitive systemic marker of inflammation and acute-phase reactions. Testing CRP concentrations at hospital admission may provide information about disease risk and overall survival. Methods: All first-ever transmittals to the department of medical and chemical laboratory diagnostics for determination of low-sensitivity CRP (n = 274 515, 44.5% male, median age 51 years) between January 1991 and July 2003 were included [median follow-up time: 4.4 years (interquartile range, 2.3–7.4 years)]. The primary endpoint was all-cause mortality. Multivariate Cox regression adjusted for sex and age was applied for analysis. Results: Compared to individuals within the reference category (CRP 80 mg/L, all P 60 years: 1.7–3.7). Interestingly, both short- and long-term mortality were associated with increasing CRP concentrations (>80 mg/L: HR 22.8 vs 1.4). Conclusion: Measurement of low-sensitivity CRP at hospital admission allowed for the identification of patients at increased risk of unfavorable outcome. Our findings indicate that close attention should be paid to hospitalized patients with high CRP not only because of very substantial short-term risk, but also long-term excess risk, the basis for which needs to be determined.
- 1 February 2008
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 54 (2) , 343-349
Open AccessC-Reactive Protein and All-Cause Mortality in a Large Hospital-Based Cohort
Background: C-reactive protein (CRP), an acute-phase protein, is a sensitive systemic marker of inflammation and acute-phase reactions. Testing CRP concentrations at hospital admission may provide information about disease risk and overall survival. Methods: All first-ever transmittals to the department of medical and chemical laboratory diagnostics for determination of low-sensitivity CRP (n = 274 515, 44.5% male, median age 51 years) between January 1991 and July 2003 were included [median follow-up time: 4.4 years (interquartile range, 2.3–7.4 years)]. The primary endpoint was all-cause mortality. Multivariate Cox regression adjusted for sex and age was applied for analysis. Results: Compared to individuals within the reference category (CRP 80 mg/L, all P 60 years: 1.7–3.7). Interestingly, both short- and long-term mortality were associated with increasing CRP concentrations (>80 mg/L: HR 22.8 vs 1.4). Conclusion: Measurement of low-sensitivity CRP at hospital admission allowed for the identification of patients at increased risk of unfavorable outcome. Our findings indicate that close attention should be paid to hospitalized patients with high CRP not only because of very substantial short-term risk, but also long-term excess risk, the basis for which needs to be determined.